vs
Avantor, Inc.（AVTR）与渤健（BIIB）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是Avantor, Inc.的1.4倍（$2.3B vs $1.7B），Avantor, Inc.净利率更高（3.1% vs -2.1%，领先5.3%），Avantor, Inc.同比增速更快（-1.4% vs -7.1%），渤健自由现金流更多（$468.0M vs $117.2M），过去两年渤健的营收复合增速更高（-0.2% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
AVTR vs BIIB — 直观对比
营收规模更大
BIIB
是对方的1.4倍
$1.7B
营收增速更快
AVTR
高出5.8%
-7.1%
净利率更高
AVTR
高出5.3%
-2.1%
自由现金流更多
BIIB
多$350.8M
$117.2M
两年增速更快
BIIB
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $2.3B |
| 净利润 | $52.4M | $-48.9M |
| 毛利率 | 31.5% | 78.3% |
| 营业利润率 | 7.6% | -2.5% |
| 净利率 | 3.1% | -2.1% |
| 营收同比 | -1.4% | -7.1% |
| 净利润同比 | -89.5% | -118.3% |
| 每股收益（稀释后） | $0.08 | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRBIIB
| Q4 25 | $1.7B | $2.3B | ||
| Q3 25 | $1.6B | $2.5B | ||
| Q2 25 | $1.7B | $2.6B | ||
| Q1 25 | $1.6B | $2.4B | ||
| Q4 24 | $1.7B | $2.5B | ||
| Q3 24 | $1.7B | $2.5B | ||
| Q2 24 | $1.7B | $2.5B | ||
| Q1 24 | $1.7B | $2.3B |
净利润AVTRBIIB
| Q4 25 | $52.4M | $-48.9M | ||
| Q3 25 | $-711.8M | $466.5M | ||
| Q2 25 | $64.7M | $634.8M | ||
| Q1 25 | $64.5M | $240.5M | ||
| Q4 24 | $500.4M | $266.7M | ||
| Q3 24 | $57.8M | $388.5M | ||
| Q2 24 | $92.9M | $583.6M | ||
| Q1 24 | $60.4M | $393.4M |
毛利率AVTRBIIB
| Q4 25 | 31.5% | 78.3% | ||
| Q3 25 | 32.4% | 73.4% | ||
| Q2 25 | 32.9% | 77.1% | ||
| Q1 25 | 33.8% | 74.1% | ||
| Q4 24 | 33.4% | 76.2% | ||
| Q3 24 | 32.9% | 74.1% | ||
| Q2 24 | 34.1% | 77.8% | ||
| Q1 24 | 34.0% | 76.3% |
营业利润率AVTRBIIB
| Q4 25 | 7.6% | -2.5% | ||
| Q3 25 | -40.0% | 22.0% | ||
| Q2 25 | 7.7% | 28.1% | ||
| Q1 25 | 9.3% | 12.8% | ||
| Q4 24 | 37.8% | 11.9% | ||
| Q3 24 | 7.3% | 18.3% | ||
| Q2 24 | 10.3% | 28.3% | ||
| Q1 24 | 8.7% | 20.3% |
净利率AVTRBIIB
| Q4 25 | 3.1% | -2.1% | ||
| Q3 25 | -43.8% | 18.4% | ||
| Q2 25 | 3.8% | 24.0% | ||
| Q1 25 | 4.1% | 9.9% | ||
| Q4 24 | 29.7% | 10.9% | ||
| Q3 24 | 3.4% | 15.8% | ||
| Q2 24 | 5.5% | 23.7% | ||
| Q1 24 | 3.6% | 17.2% |
每股收益（稀释后）AVTRBIIB
| Q4 25 | $0.08 | $-0.35 | ||
| Q3 25 | $-1.04 | $3.17 | ||
| Q2 25 | $0.09 | $4.33 | ||
| Q1 25 | $0.09 | $1.64 | ||
| Q4 24 | $0.73 | $1.82 | ||
| Q3 24 | $0.08 | $2.66 | ||
| Q2 24 | $0.14 | $4.00 | ||
| Q1 24 | $0.09 | $2.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | — |
| 总债务越低越好 | $3.9B | $6.3B |
| 股东权益账面价值 | $5.6B | $18.3B |
| 总资产 | $11.8B | $29.4B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资AVTRBIIB
| Q4 25 | $365.4M | — | ||
| Q3 25 | $251.9M | — | ||
| Q2 25 | $449.4M | — | ||
| Q1 25 | $315.7M | — | ||
| Q4 24 | $261.9M | — | ||
| Q3 24 | $285.3M | — | ||
| Q2 24 | $272.6M | — | ||
| Q1 24 | $234.9M | — |
总债务AVTRBIIB
| Q4 25 | $3.9B | $6.3B | ||
| Q3 25 | $3.9B | $6.3B | ||
| Q2 25 | $4.2B | $6.3B | ||
| Q1 25 | $4.1B | $4.5B | ||
| Q4 24 | $4.1B | $6.3B | ||
| Q3 24 | $4.9B | $4.5B | ||
| Q2 24 | $5.1B | $6.3B | ||
| Q1 24 | $5.3B | $6.3B |
股东权益AVTRBIIB
| Q4 25 | $5.6B | $18.3B | ||
| Q3 25 | $5.6B | $18.2B | ||
| Q2 25 | $6.3B | $17.6B | ||
| Q1 25 | $6.1B | $17.0B | ||
| Q4 24 | $6.0B | $16.7B | ||
| Q3 24 | $5.6B | $16.4B | ||
| Q2 24 | $5.4B | $15.9B | ||
| Q1 24 | $5.3B | $15.2B |
总资产AVTRBIIB
| Q4 25 | $11.8B | $29.4B | ||
| Q3 25 | $11.7B | $29.2B | ||
| Q2 25 | $12.8B | $28.3B | ||
| Q1 25 | $12.3B | $28.0B | ||
| Q4 24 | $12.1B | $28.0B | ||
| Q3 24 | $12.8B | $28.3B | ||
| Q2 24 | $12.7B | $26.8B | ||
| Q1 24 | $12.8B | $26.6B |
负债/权益比AVTRBIIB
| Q4 25 | 0.71× | 0.34× | ||
| Q3 25 | 0.69× | 0.35× | ||
| Q2 25 | 0.67× | 0.36× | ||
| Q1 25 | 0.67× | 0.27× | ||
| Q4 24 | 0.68× | 0.38× | ||
| Q3 24 | 0.89× | 0.28× | ||
| Q2 24 | 0.94× | 0.40× | ||
| Q1 24 | 1.00× | 0.41× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $511.9M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $468.0M |
| 自由现金流率自由现金流/营收 | 7.0% | 20.5% |
| 资本支出强度资本支出/营收 | 2.1% | 1.9% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $2.1B |
8季度趋势，按日历期对齐
经营现金流AVTRBIIB
| Q4 25 | $152.7M | $511.9M | ||
| Q3 25 | $207.4M | $1.3B | ||
| Q2 25 | $154.4M | $160.9M | ||
| Q1 25 | $109.3M | $259.3M | ||
| Q4 24 | $173.3M | $760.9M | ||
| Q3 24 | $244.8M | $935.6M | ||
| Q2 24 | $281.1M | $625.8M | ||
| Q1 24 | $141.6M | $553.2M |
自由现金流AVTRBIIB
| Q4 25 | $117.2M | $468.0M | ||
| Q3 25 | $171.7M | $1.2B | ||
| Q2 25 | $124.8M | $134.3M | ||
| Q1 25 | $81.3M | $222.2M | ||
| Q4 24 | $145.8M | $721.6M | ||
| Q3 24 | $204.0M | $900.6M | ||
| Q2 24 | $235.3M | $592.3M | ||
| Q1 24 | $106.9M | $507.3M |
自由现金流率AVTRBIIB
| Q4 25 | 7.0% | 20.5% | ||
| Q3 25 | 10.6% | 48.4% | ||
| Q2 25 | 7.4% | 5.1% | ||
| Q1 25 | 5.1% | 9.1% | ||
| Q4 24 | 8.6% | 29.4% | ||
| Q3 24 | 11.9% | 36.5% | ||
| Q2 24 | 13.8% | 24.0% | ||
| Q1 24 | 6.4% | 22.1% |
资本支出强度AVTRBIIB
| Q4 25 | 2.1% | 1.9% | ||
| Q3 25 | 2.2% | 1.8% | ||
| Q2 25 | 1.8% | 1.0% | ||
| Q1 25 | 1.8% | 1.5% | ||
| Q4 24 | 1.6% | 1.6% | ||
| Q3 24 | 2.4% | 1.4% | ||
| Q2 24 | 2.7% | 1.4% | ||
| Q1 24 | 2.1% | 2.0% |
现金转化率AVTRBIIB
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | 2.73× | ||
| Q2 25 | 2.39× | 0.25× | ||
| Q1 25 | 1.69× | 1.08× | ||
| Q4 24 | 0.35× | 2.85× | ||
| Q3 24 | 4.24× | 2.41× | ||
| Q2 24 | 3.03× | 1.07× | ||
| Q1 24 | 2.34× | 1.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
